OakChart

BridgeBio Oncology Therapeutics Inc

BBOTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.56+0.36 (16.36%)
2026-11-12 02:11 CET
Market cap
205.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-171.53 USD m
Free cash flow, TTM
-151.03 USD m
EPS diluted, TTM
-1,232.22
P/E
-
Compare

Price

BBOT against its 20, 50 and 200-day averages
2050200beatmiss
2.004.006.008.0010.001.4M2.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BBOTclose 2.5620-day 2.5650-day 3.92200-day 7.752.5652w low

82.8% under the 52-week high of 14.87 on 8 Dec 2025. 52-week low 1.98 on 6 Nov 2026. Last 15 sessions, 48.8% high to low

Volume 2.48× normal · the line is the 50-bar volume average

Profile

BBOT
52-week range, 4% of the way up
1.9814.87

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

Employees92
IPOFeb 09, 2024
Beta0.92
ATR, 14d0.26
Rel volume2.48
Short float7.67%
Insider own43.59%
Inst own56.62%

Snapshot

6 groups

Valuation

Index-
Market Cap205.24M
Enterprise Value13.75M
Income-171.53M
Sales0.00M
Book/sh3.66
Cash/sh2.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOFeb 09, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.70
P/C1.06
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.08
Current Ratio4.08
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-1232.22
EPS next Y-1.90
EPS next Q-0.47
EPS this Y44.96%
EPS next Y19.91%
EPS next 5Y25.21%
EPS past 3/5Y-2681.49% -572.84%
Sales past 3/5Y- -
EPS Y/Y TTM-132725.78%
Sales Y/Y TTM-
EPS Q/Q58.59%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.37.68% -

Ownership

Insider Own43.59%
Insider Trans0.00%
Inst Own56.62%
Inst Trans7.82%
ROA-41.28%
ROE-46.35%
ROIC-58.11%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.04%
SMA50-34.64%
SMA200-66.95%
Trades-

Technical

Shs Outstand80.23M
Shs Float45.23M
Short Float7.67%
Short Ratio6.04
Short Interest3.47M
52W High14.87 -82.78%
52W Low1.98 29.29%
Volatility12.53% 9.07%
ATR (14)0.26
RSI (14)40.05
Beta0.92
Rel Volume2.48
Avg Volume574.43K
Volume1,423,911

Performance

Perf Week11.30%
Perf Month-13.22%
Perf Quarter-72.26%
Perf Half Y-68.32%
Perf YTD-79.55%
Perf Year-79.92%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.10
Target Price17.56
Prev Close2.20
Price2.56
Change %16.36%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Jul 08, 2026InitiatedJJP MorganOverweight$27+954.7%
Jun 22, 2026ResumedOOppenheimerOutperform$22+759.4%
May 11, 2026InitiatedCCanaccord GenuityBuy$23+798.4%
Feb 11, 2026InitiatedSStifelBuy$23+798.4%
Jan 09, 2026InitiatedRRaymond JamesOutperform$24+837.5%
Dec 05, 2025InitiatedMMorgan StanleyOverweight$20+681.3%
Sep 17, 2025InitiatedLLeerink PartnersOutperform$25+876.6%
Sep 15, 2025InitiatedHH.C. WainwrightBuy$27+954.7%
Aug 15, 2025InitiatedPPiper SandlerOverweight$21+720.3%

Peers

Mkt cap
TickerCompanyMkt cap
ERASErasca Inc5.88B
VSTMVerastem Inc1.15B
RVMDRevolution Medicines Inc39.08B
IMRXImmuneering Corp245.45M
CELCCelcuity Inc3.16B
BLSMBlossomHill Therapeutics Inc512.38M
CRDFCardiff Oncology Inc59.54M
ORICORIC Pharmaceuticals Inc932.88M
TYRATyra Biosciences Inc1.44B
BDTXBlack Diamond Therapeutics Inc92.50M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
LABUDirexion Daily S&P Biotech Bull 3X ETFAUM: 583.37M
SGRWHarbor Active Small Cap Growth ETFAUM: 28.06M

News

latest 14 of 84
  • BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire) +16.36%
  • BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.51%
  • Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use (BioPharma Dive) -10.33%
  • BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers (GlobeNewswire) -23.76%
  • BBOT to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
  • BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
  • BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
  • BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Lilly tumbles on Foundayos shaky week; FDA to issue vouchers for psychedelics (BioPharma Dive)
  • BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 (GlobeNewswire) -6.24%
  • BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman (GlobeNewswire)
  • BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 (GlobeNewswire)
  • BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.430-0.690-0.4260.000.0010
2026Q22026-08-11-0.705-0.565-705.20.000.0010
2026Q12026-05-12-0.526-0.512-526.120.000.0010
2025Q42026-03-05-0.490-0.633-0.4850.000.009
2025Q32025-11-12-1.030-0.382-1.0290.000.006
2025Q22025-09-03-49.615-42.4500.0390.000.003
2025Q12025-05-28-50.125--0.0210.00--
2026Q4---0.474--0.0010
2027Q1---0.486--0.005
2027Q2---0.516--0.005
2027Q3---0.466--0.005
2027Q4---0.472--0.005
2028Q1---0.440--0.001
2028Q2---0.440--0.001
2028Q3---0.440--0.001
2028Q4---0.280--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-4.300-3.216-3.9500.000.00
2026FY--2.367--0.00
2027FY--1.896--0.00
2028FY--1.799--0.00
2029FY--1.424--25.94
2030FY--1.123--105.85

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-117000.000.000.00
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-08-127000.000.000.00
2026Q4S2026-07-077000.000.000.00
2026Q4S2026-05-136000.000.000.00
2026Q4S2026-03-066000.000.000.00
2026Q4S2026-02-096000.000.000.00
2026Q4S2026-01-085000.000.000.00
2026Q4S2025-11-134000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4R2026-11-111081-0.47-0.69-0.27
2026Q4R2026-11-101003-0.67-0.72-0.57
2026Q4R2026-10-271003-0.67-0.72-0.57

Estimate history

EPS, annual-0.0020-0.002-5756.413-4.304-1232.2248
Period20212022202320242025TTM
EPS, quarterly0.0990.083-0.0210.039-1.029-0.485-526.115-705.199-0.426
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.48520.48520.4850.02879.99280.235
Period20212022202320242025MRQ
Shares, quarterly23.50923.50923.50923.50979.19779.99280.08980.11580.235
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.760.610.210.000.000.00
Gross Profit-0.76-0.61-0.210.000.000.00
Selling, General and Administrative Excl. Other186.50145.2180.660.040.000.04
Research and Development156.69121.2073.11---
Other Operating Expense0.000.000.000.000.000.00
Operating Income-187.26-145.82-80.86-0.04-0.00-0.04
Interest Expense0.000.000.00---
Unusual Expense0.000.720.560.000.000.00
Net Income Before Taxes-171.53-134.04-74.28-0.04-0.00-0.04
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-171.53-134.04-74.28-0.04-0.00-0.04
Net Income From Continuing Operations-171.53-134.04-74.28-0.04-0.00-0.04
Net Income-171.53-134.04-74.28-0.04-0.00-0.04
EPS (Recurring)-2.14-4.29-5,725.82-0.00-0.00-0.00
EPS (Basic, Before Extraordinaries)-1,232.22-4.30-5,756.41-0.00-0.00-0.00
EPS (Diluted)-1,232.22-4.30-5,756.41-0.00-0.00-0.00
EBITDA-186.50-145.21-80.66-0.04-0.00-0.04
Non-Operating Income (Expense)15.7312.507.150.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense18.795.874.42---
Shares Outstanding80.2379.990.0320.4820.4820.48
Market Capitalization205.25176.38989.46---

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.190.190.190.190.420.000.000.00
Gross Profit-0.19-0.19-0.19-0.19-0.420.000.000.00
Selling, General and Administrative Excl. Other37.3060.0045.9943.2148.771.122.420.22
Research and Development29.5949.2339.8038.0734.64---
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-37.49-60.19-46.18-43.41-49.18-1.12-2.42-0.22
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-34.18-56.45-42.11-38.80-44.760.92-0.491.95
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-34.18-56.45-42.11-38.80-44.760.92-0.491.95
Net Income From Continuing Operations-34.18-56.45-42.11-38.80-44.760.92-0.491.95
Net Income-34.18-56.45-42.11-38.80-44.760.92-0.491.95
EPS (Recurring)-0.43-705.20-526.11-0.49-1.030.04-0.020.08
EPS (Basic, Before Extraordinaries)-0.43-705.20-526.11-0.48-1.030.04-0.020.08
EPS (Diluted)-0.43-705.20-526.11-0.48-1.030.04-0.020.08
EBITDA-37.30-60.00-45.99-43.21-48.77-1.12-2.42-0.22
Non-Operating Income (Expense)3.313.734.074.614.422.041.932.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.757.233.872.951.430.040.060.08
Price To Earnings Ratio----57.7057.15--
Shares Outstanding80.2380.1280.0979.9979.2023.5123.5123.51
Market Capitalization205.25610.42716.291,001.46970.37961.15--

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments425.46155.630.000.000.00
Short Term Receivables0.390.080.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets6.552.980.000.000.00
Total Current Assets432.40158.690.000.000.00
Net Property, Plant & Equipment3.290.490.000.000.00
Total Investments and Advances0.130.130.000.000.00
Intangible Assets-0.000.000.000.00
Deferred Tax Assets0.700.01---
Other Assets12.574.990.330.140.14
Total Assets449.08164.310.330.140.14
Short Term Debt Incl. Current Port. of LT Debt0.520.000.070.040.04
Accounts Payable1.373.070.000.000.00
Other Current Liabilities33.1516.510.330.120.13
Total Current Liabilities35.0419.580.400.170.16
Long Term Debt2.240.000.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities0.700.01---
Other Liabilities0.000.000.000.000.00
Total Liabilities37.9819.590.400.170.16
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.00323.360.000.000.00
Common Equity411.10-178.64-0.06-0.02-0.02
Total Shareholders Equity411.10144.72-0.06-0.02-0.02
Accumulated Minority Interest0.000.000.000.000.00
Total Equity411.10144.72-0.06-0.02-0.02
Total Liabilities & Stockholders Equity449.08164.310.330.140.14
Book Value Per Share5.14-6,286.71-0.00-0.00-0.00
Tangible Book Value Per Share5.14-6,286.71-0.00-0.00-0.00
Full-Time Employees9233--
Price to Book Ratio0.552.19---
Return on Assets-41.66-90.22-17.46-2.44-
Return on Equity-44.70-102.69---
Return on Invested Capital-32.43-51.32---
Quick Ratio12.348.100.000.000.00
Current Ratio12.348.100.000.000.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-171.53-134.04-74.28-0.04-0.00-0.04
Depreciation0.760.610.21---
Other Funds (Non Cash)19.1713.113.450.03--
Funds from Operations-151.60-120.33-70.62-0.010.000.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.736.4315.590.010.00-
Cash from Operating Activities-150.88-113.89-55.030.000.000.00
Capital Expenditures-0.16-0.61-0.050.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-181.4273.93-122.890.000.000.00
Purchase of Investments-357.17-83.92-154.430.000.000.00
Sale Or Maturity of Investments175.76157.8631.540.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.002.410.000.000.00
Cash from Investing Activities-181.5773.33-120.530.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock374.43395.72205.230.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock374.43395.72205.230.000.000.00
Proceedsfrom Stock Options373.46395.68205.180.000.000.00
Issuance or Reduction of Debt, Net-373.460.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.79-12.321.060.000.000.00
Other Financing Activities Uses-0.79-12.320.000.000.000.00
Cash from Financing Activities0.19383.40206.290.000.000.00
Net Change in Cash-332.26342.8430.73---
Free Cash Flow-151.03-114.50-55.080.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments193.87225.71252.28425.46468.290.66
Short Term Receivables0.150.660.150.390.230.00
Inventories0.000.000.000.000.000.00
Other Current Assets14.3016.0114.086.557.500.21
Total Current Assets208.33242.38266.50432.40476.010.88
Net Property, Plant & Equipment2.802.983.163.293.270.00
Total Investments and Advances121.59118.55136.750.130.13196.51
Intangible Assets-----0.00
Deferred Tax Assets---0.70--
Other Assets13.5012.7911.2412.575.380.00
Total Assets346.22376.71417.65449.08484.79197.39
Short Term Debt Incl. Current Port. of LT Debt0.570.550.540.520.510.00
Accounts Payable10.266.7312.091.373.650.00
Other Current Liabilities40.1944.3530.6333.1531.562.63
Total Current Liabilities51.0351.6343.2635.0435.712.63
Long Term Debt1.811.962.112.242.380.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.70--
Other Liabilities0.000.000.000.000.005.52
Total Liabilities52.8453.5945.3737.9838.098.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity293.39323.11372.28411.10446.70189.24
Total Shareholders Equity293.39323.11372.28411.10446.70189.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity293.39323.11372.28411.10446.70189.24
Total Liabilities & Stockholders Equity346.22376.71417.65449.08484.79197.39
Book Value Per Share3.664.034.655.145.648.05
Tangible Book Value Per Share3.664.034.655.145.648.05
Full-Time Employees---9281-
Price to Book Ratio0.701.641.742.221.441.42
Return on Assets-41.28-63.44-40.68-25.83-12.522.44
Return on Equity-46.35-71.09-44.51-27.72-13.382.53
Return on Invested Capital-11.58-17.37-11.25-9.39-9.970.49
Quick Ratio4.084.696.1612.3413.330.33
Current Ratio4.084.696.1612.3413.330.33

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-34.18-56.45-42.11-38.80-95.680.92
Depreciation0.190.190.190.19--
Other Funds (Non Cash)4.877.643.802.8614.22-2.04
Funds from Operations-29.11-48.62-38.12-35.75-81.04-1.12
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.754.262.21-6.4910.420.82
Cash from Operating Activities-28.36-44.36-35.92-42.23-70.63-0.30
Capital Expenditures-0.01-0.05-0.02-0.07-0.530.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments50.3545.78-285.387.8466.090.00
Purchase of Investments-16.95-7.54-311.64-21.04-62.880.00
Sale Or Maturity of Investments67.3053.3126.2628.88128.980.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities50.3445.73-285.417.7765.560.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.480.040.42373.5022.220.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.480.040.42373.5022.220.00
Proceedsfrom Stock Options0.000.000.00373.4622.220.00
Issuance or Reduction of Debt, Net0.000.000.00-373.46373.460.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.040.00-0.12-0.63-11.690.00
Other Financing Activities Uses-0.040.00-0.12-0.63-11.690.00
Cash from Financing Activities0.440.040.29-0.59383.990.00
Net Change in Cash22.421.41-321.03-35.05378.92-0.30
Free Cash Flow-28.38-44.41-35.94-42.31-71.16-0.30

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.67%3.5M45.2M536.61K
2026-10-158.50%3.8M45.2M467.10K
2026-09-307.05%3.4M47.9M452.03K
2026-09-157.52%3.6M47.9M465.09K
2026-08-3112.95%6.2M47.8M371.89K
2026-08-1412.14%5.8M47.8M404.85K
2026-07-3112.17%5.8M47.9M411.52K
2026-07-1511.89%5.7M47.9M461.48K
2026-06-3012.01%5.2M43.4M456.21K
2026-06-159.08%3.9M43.4M355.66K
2026-05-298.91%3.9M43.4M347.85K
2026-05-157.55%3.3M43.4M326.48K
2026-04-307.61%3.3M43.6M320.03K
2026-04-157.43%3.2M43.6M266.75K
2026-03-315.50%2.4M43.6M276.06K
2026-03-135.18%2.3M43.6M283.39K
2026-02-275.34%2.3M43.6M283.83K
2026-02-135.38%2.3M43.6M258.75K
2026-01-304.96%2.2M43.6M230.62K
2026-01-155.02%2.2M43.6M213.72K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-058-KCurrent report2026-10-30SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10EFFECTEffectiveness filing by commission orderSEC
2026-09-08EFFECTEffectiveness filing by commission orderSEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-01S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-01POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-12424B3SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-06SCHEDULE 13D/ASEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-22424B3SEC
2026-06-228-KCurrent report2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DEERFIELD MANAGEMENT COMPANY, L.P.6.10%
Omega Fund Management, LLC4.11%
EcoR1 Capital, LLC3.52%
Alphabet Inc.3.52%
WELLINGTON MANAGEMENT GROUP LLP3.48%
Enavate Sciences GP, LLC3.28%
CITADEL ADVISORS LLC3.27%
REGENTS OF THE UNIVERSITY OF CALIFORNIA3.13%
Novo Holdings A/S2.81%
BlackRock, Inc.2.69%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.78%
BlackRock Health Sciences Opportunities Portfolio1.10%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.02%
VANGUARD EXTENDED MARKET INDEX FUND0.67%
iShares Biotechnology ETF0.38%
BlackRock Health Sciences Term Trust0.33%
Fidelity Extended Market Index Fund0.30%
Select Biotechnology Portfolio0.30%
Schwab U.S. Small-Cap ETF0.28%
T. Rowe Price Health Sciences Fund, Inc.0.28%

OakChart. BBOT. Cached 15 minutes.

Some panels did not load: insider.